Developments in MRI-targeted prostate biopsy.
Developments in MRI-targeted prostate biopsy.
复制标题
DOI：
10.1097/mou.0000000000000683
复制
发表时间：
2020-01
影响因子：
2.5
通讯作者：
J. Norris;A. Kinnaird;D. Margolis;A. Padhani;J. Walz;V. Kasivisvanathan
中科院分区：
文献类型：
--
作者：
J. Norris;A. Kinnaird;D. Margolis;A. Padhani;J. Walz;V. Kasivisvanathan
mri靶向前列腺活检可能是一种有吸引力的替代系统活检诊断临床意义的前列腺癌。在这篇叙述性回顾中，我们讨论了过去24个月来mri靶向前列腺活检进展的新进展。与目前的系统经直肠超声引导（TRUS）活检的护理标准相比，mri靶向活检通过减少所需活检的总次数，维持或改善重要的前列腺癌检测，并减少临床无关紧要的前列腺癌的检测，提供了更高的诊断准确性。系统前列腺活检与mri靶向活检相结合的必要性仍然存在争议。使用MRI-超声融合系统进行病灶定位有望优化重要的癌症检测，但最近的证据表明，额外的认知活检核心仍然有助于检测其他癌症。对MRI阳性的男性进行MRI靶向活检比对所有男性进行系统活检有许多好处，因此，可能成为诊断临床意义重大的前列腺癌的新标准。
PURPOSE OF REVIEW MRI-targeted prostate biopsy may be an attractive alternative to systematic biopsy for diagnosing clinically significant prostate cancer. In this narrative review, we discuss the new developments that have occurred in the advancement of MRI-targeted prostate biopsy, over the past 24 months. RECENT FINDINGS MRI-targeted biopsy offers enhanced diagnostic accuracy, when compared with the current standard of care of systematic transrectal ultrasound-guided (TRUS) biopsy, by decreasing the overall number of biopsies needed, maintaining or improving significant prostate cancer detection, and reducing the detection of clinically insignificant prostate cancer. The necessity of combining systematic prostate biopsy with MRI-targeted biopsy is still debated. The use of MRI--ultrasound fusion systems for lesion-targeting is promising for optimizing significant cancer detection, but recent evidence suggests that additional cognitive biopsy cores are still useful in detecting additional cancers. SUMMARY MRI-targeted biopsy in selected men with positive MRI offers a number of benefits over systematic biopsy in all men, and as such, may emerge as the new standard of care for the diagnosis of clinically significant prostate cancer.